Balanced Portfolio Recommendations: SELL – Clinuvel (CUV)
We recommend selling CUV due to the current broader market weakness, with the goal of moving to a cash position to mitigate risk and capitalize on potential future buying opportunities.
CUV
Balanced Portfolio Recommendation: Switch 2% ResMed (RMD) to Clinuvel Pharmaceuticals Ltd (CUV)
With the recent run in RMD we are looking to bank some profits here at $29 (+20%) while we see further upside in the stock, the risk that further developments in the GLP-1 space could derail this recent run. Particularly a study due from Eli Lily a maker of Zepbound in the next month.
We still prefer exposure in the healthcare space and are recommending a switch of our RMD allocation to Clinuvel (CUV) a skin disease treatment for sufferers of EPP. They are also in Phase 2 of a stroke treatment drug which is looking promising